PFGT.F Stock Overview
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Pacific Edge Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | NZ$0.061 |
| 52 Week High | NZ$0.28 |
| 52 Week Low | NZ$0.025 |
| Beta | 1.01 |
| 1 Month Change | 10.89% |
| 3 Month Change | 18.64% |
| 1 Year Change | -79.08% |
| 3 Year Change | -92.90% |
| 5 Year Change | -72.23% |
| Change since IPO | -86.42% |
Recent News & Updates
Recent updates
Shareholder Returns
| PFGT.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -2.5% | -3.2% |
| 1Y | -79.1% | -3.7% | 19.3% |
Return vs Industry: PFGT.F underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: PFGT.F underperformed the US Market which returned 20.2% over the past year.
Price Volatility
| PFGT.F volatility | |
|---|---|
| PFGT.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PFGT.F has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine PFGT.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 114 | Peter Meintjes | www.pacificedgedx.com |
Pacific Edge Limited, a cancer diagnostic company, researches, develops, and commercializes diagnostic and prognostic tools for the early detection and management of cancers in New Zealand, the United States, Australia, and Singapore. The company operates in two segments, Commercial and Research. It offers Cxbladder, a genomic urine tests for the detection and management of bladder cancer.
Pacific Edge Limited Fundamentals Summary
| PFGT.F fundamental statistics | |
|---|---|
| Market cap | US$40.62m |
| Earnings (TTM) | -US$18.63m |
| Revenue (TTM) | US$15.02m |
2.7x
P/S Ratio-2.2x
P/E RatioIs PFGT.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PFGT.F income statement (TTM) | |
|---|---|
| Revenue | NZ$25.52m |
| Cost of Revenue | NZ$11.02m |
| Gross Profit | NZ$14.50m |
| Other Expenses | NZ$46.14m |
| Earnings | -NZ$31.65m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.039 |
| Gross Margin | 56.80% |
| Net Profit Margin | -124.01% |
| Debt/Equity Ratio | 0% |
How did PFGT.F perform over the long term?
See historical performance and comparison